1. 4: DHMEQ a novel therapeutic option for the treatment of inflammatory mediated cisplatin resistant non-small cell lung cancer. (January 2015) Authors: Baird, A.-M.; Godwin, P.; Heavey, S.; Barr, M.; Umezawa, K.; Cuffe, S.; Finn, S.; O'Byrne, K.J.; Gately, K.A. Journal: Lung cancer Issue: Volume 87(2015)Supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 5: Mechanisms of resistance to dual PI3K–mTOR inhibition in NSCLC cell lines. (January 2015) Authors: Heavey, S.; Dowling, P.; Barr, M.; Cuffe, S.; Finn, S.; O'Byrne, K.J.; Gately, K.A. Journal: Lung cancer Issue: Volume 87(2015)Supplement 1 Page Start: S2 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Spatial transcriptomics analysis of co-targeted PIM and PI3 K/mTOR in multikinase inhibitor and single kinase inhibitor combination-treated patient-derived prostate cancer explants. (October 2022) Authors: Okoli, U.; Akman, G.; Thavarajah, V.; Carmona Echeverria, L.M.; Griffin, J.; Ohayi, S.R.; Freeman, A.; Haider, A.; Shaw, G.; Sridhar, A.N.; Kelly, J.; Simpson, B.; Pye, H.; Crompton, J.; Whitaker, H.; Cheema, U.; Heavey, S. Journal: European journal of cancer Issue: Volume 174(2022)Supplement 1 Page Start: S64 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗